Observational Study of Lymphoma Cells
This study is looking at lymphoma cells to better understand how Hodgkin's disease and non-Hodgkin's lymphoma grow and spread. Researchers will collect tumor tissue from people diagnosed with these conditions to study the cells' molecular and cell biology. The goal is to learn more about lymphoma, which could help develop new treatments or ways to track how well treatments are working in the future. You can join if you have Hodgkin's disease or non-Hodgkin's lymphoma, regardless of its type or stage, and are having a routine procedure to collect tissue. This is an observational study, meaning no specific interventions are being tested. The study is ongoing and aims to enroll up to 9999 participants.
- Study design
- This is an observational study that plans to include up to 9999 participants. It is not testing any specific interventions or treatments.
- What's involved
- You would provide tumor tissue collected during a routine procedure, such as a lymph node excision, tonsillectomy, or surgery for sleep apnea.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will continue indefinitely to collect tumor tissue and characterize lymphoma cells.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ronald Levy, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Collection of tumor tissue to characterize the molecular and cell biology of tumor cells in lymphoma.The study will continue indefinitely.